GlaxoSmithkline Pharmaceuticals Limited (GLAXO.BO)

2,093.85 -9.70 (-0.46%) At close: 03:29PM IST

GlaxoSmithkline Pharmaceuticals Limited

GSK House
Dr. Annie Besant Road
Mumbai 400030
India
91 22 2495 9595
https://india-pharma.gsk.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 3,680

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Bhushan Akshikar	MD & Executive Director	32.37M	N/A	N/A
Mr. Juby Chandy	Whole-Time Director & CFO	54.12M	N/A	1977
Mr. Ajay A. Nadkarni	VP of Administration & Real Estate and Company Secretary	N/A	N/A	N/A
Mr. Amit G. Pandey	Executive Vice President of Legal	N/A	N/A	N/A
Ms. Simrat Sohal	Vice President of Ethics & Compliance	N/A	N/A	N/A
Mr. Ransom D'Souza	Executive Vice President of Communications & Government Affairs	N/A	N/A	N/A
Mr. Chinmay Sharma	Executive Vice President of Human Resources	N/A	N/A	N/A
Ms. Sukanya Choudhary	Executive Vice-President of Regulatory Affairs	N/A	N/A	N/A
Mr. Sougato Mitra	Head of Specialty	N/A	N/A	N/A
Dr. Rashmi Hegde M.D.	Executive Vice President of Medical	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Corporate governance

GlaxoSmithkline Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.